3/25
09:00 am
nxgl
NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st
Medium
Report
NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st
3/12
03:46 pm
nxgl
NexGel (NXGL) had its price target lowered by Maxim Group from $6.00 to $2.00. They now have a "buy" rating on the stock.
Low
Report
NexGel (NXGL) had its price target lowered by Maxim Group from $6.00 to $2.00. They now have a "buy" rating on the stock.
3/12
09:05 am
nxgl
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products [Yahoo! Finance]
High
Report
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products [Yahoo! Finance]
3/12
08:45 am
nxgl
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products
Medium
Report
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products
3/12
08:42 am
nxgl
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities [Yahoo! Finance]
Medium
Report
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities [Yahoo! Finance]
3/10
09:04 am
nxgl
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products [Yahoo! Finance]
Medium
Report
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products [Yahoo! Finance]
3/10
08:45 am
nxgl
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products
High
Report
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products
2/10
09:00 am
nxgl
NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence
Low
Report
NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence